Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Finance

04 October 2021

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ASRS, ESGCT and Several Investor and Industry Meetings in October

07 Sep 2021

Redburn Gene Therapy Virtual Summit 2021

01 September 2021

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September

29 July 2021

GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update

05 July 2021

GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France

20 April 2021

GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update

08 April 2021

GenSight Biologics Announces the Filing of its 2020 Universal Registration Document

26 March 2021

GenSight Biologics successfully raises €30 million in an oversubscribed private placement with European and US institutional investors

25 March 2021

GenSight Biologics launches a reserved offering of c. €25 million by means of an accelerated bookbuilding process

10 March 2021

GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page